Biological therapy for the inner ear.
Biological therapy for the inner ear has the potential to revolutionise the treatment of sensorineural hearing loss, the most common form of deafness. Progress in the molecular understanding of hearing and hearing loss, combined with advances in the fields of both gene and cellular therapy for the inner ear, is providing a robust foundation from which clinical translation is plausible. Potential areas of interest in gene therapy and its preclinical application to deafness are reviewed, and experimental progress that has occurred in cellular therapy for the inner ear is examined.
Patel
Nirmal P
NP
Laboratory of Molecular Otology, Department of Otolaryngology, New York University School of Medicine, NY 10016, USA.
Mhatre
Anand N
AN
Lalwani
Anil K
AK
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics / Q000502:physiology; D002454:Cell Differentiation / Q000235:genetics; D017690:Cell Transplantation / Q000379:methods; D002645:Chickens; D002682:Chinchilla; D003051:Cochlea / Q000166:cytology / Q000503:physiopathology / Q000601:surgery; D000229:Dependovirus / Q000235:genetics; D016057:Evoked Potentials, Auditory, Brain Stem; D005727:Ganglia, Spinal / Q000166:cytology; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage / Q000627:therapeutic use; D006168:Guinea Pigs; D006319:Hearing Loss, Sensorineural / Q000628:therapy*; D006801:Humans; D007260:Infusion Pumps; D051379:Mice; D008845:Microinjections; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use; D010498:Perilymph; D051381:Rats; D033581:Stem Cell Transplantation; D019076:Transgenes
D000975:Antioxidants; D051792:Basic Helix-Loop-Helix Proteins; D009414:Nerve Growth Factors; C500942:ATOH1 protein, human